Literature DB >> 11736958

High prevalence of low serum vitamin B12 in a multi-ethnic Israeli population.

Y Gielchinsky1, D Elstein, R Green, J W Miller, Y Elstein, N Algur, A Lahad, E Shinar, A Abrahamov, A Zimran.   

Abstract

This study ascertained serum vitamin B12 levels among patients with Gaucher disease and among healthy Israelis. Serum B12 and metabolites' levels were studied in consecutive adult patients with Gaucher disease not treated with enzyme plus Ashkenazi Jewish neighbour-controls, together with healthy blood-donor volunteers of various ethnicities. Each group showed a high incidence of low serum B12 concentrations, with a 22.3% incidence among Ashkenazi Jews and 40% among patients with Gaucher disease. These findings raise questions on the individual and community levels of serum B12. We recommend evaluation of B12 levels among geographically contingent peoples.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736958     DOI: 10.1046/j.1365-2141.2001.03156.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Nutritional deficiencies in the pediatric age group in a multicultural developed country, Israel.

Authors:  Motti Haimi; Aaron Lerner
Journal:  World J Clin Cases       Date:  2014-05-16       Impact factor: 1.337

Review 2.  The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Authors:  T M Cox; J M F G Aerts; G Andria; M Beck; N Belmatoug; B Bembi; R Chertkoff; S Vom Dahl; D Elstein; A Erikson; M Giralt; R Heitner; C Hollak; M Hrebicek; S Lewis; A Mehta; G M Pastores; A Rolfs; M C Sa Miranda; A Zimran
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 3.  'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

Authors:  M Biegstraaten; I N van Schaik; J M F G Aerts; C E M Hollak
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.750

4.  Assessment of cellular cobalamin metabolism in Gaucher disease.

Authors:  Suelen Porto Basgalupp; Marina Siebert; Charles Ferreira; Sidney Behringer; Ute Spiekerkoetter; Luciana Hannibal; Ida Vanessa Doederlein Schwartz
Journal:  BMC Med Genet       Date:  2020-01-13       Impact factor: 2.103

Review 5.  Novel Management and Screening Approaches for Haematological Complications of Gaucher's Disease.

Authors:  Pilar Giraldo; Marcio Andrade-Campos
Journal:  J Blood Med       Date:  2021-12-07

Review 6.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162

7.  Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.

Authors:  Derralynn Hughes; Maria Domenica Cappellini; Marc Berger; Jan Van Droogenbroeck; Maaike de Fost; Dragana Janic; Theodore Marinakis; Hanna Rosenbaum; Jesús Villarubia; Elena Zhukovskaya; Carla Hollak
Journal:  Br J Haematol       Date:  2007-07-26       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.